Evolving role of lenvatinib in management of unresectable HCC
20 Feb 2026
byDr. Krittiya Korphaisarn, Mahidol University, Bangkok, Thailand; Prof. Joseph Llovet, University of Barcelona, Barcelona, Spain; Prof. Masatoshi Kudo, Kindai University, Osaka, Japan
At an industry-sponsored symposium during the
International Liver Cancer Association (ILCA) 2025 Annual Conference, Dr
Krittiya Korphaisarn of Mahidol University, Bangkok, Thailand, reviewed
systemic therapy for advanced hepatocellular carcinoma (HCC), focusing on
lenvatinib as a second-line (2L) option following immunotherapy (IO). Professor
Joseph Llovet of the University of Barcelona, Barcelona, Spain, and Tisch
Cancer Institute at Mount Sinai, New York, US, and Professor Masatoshi Kudo of
the Kindai University, Osaka, Japan, discussed the integration of systemic and
locoregional treatments for intermediate HCC to optimize outcomes through
multidisciplinary care.
